Comparative Pharmacology
Head-to-head clinical analysis: NUCYNTA ER versus TRAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUCYNTA ER versus TRAL.
NUCYNTA ER vs TRAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tapentadol is a mu-opioid receptor agonist and norepinephrine reuptake inhibitor, providing analgesic effects through opioid receptor activation and modulation of descending pain pathways.
Tralokinumab is a human monoclonal antibody that specifically binds to interleukin-13 (IL-13) and inhibits its interaction with the IL-13 receptor α1 and α2 subunits. This blockade reduces IL-13-mediated signaling, which is implicated in the pathophysiology of atopic dermatitis, including inflammation, pruritus, and skin barrier dysfunction.
100 mg orally every 12 hours, titrated from 50 mg every 12 hours; maximum 200 mg every 12 hours.
10 mg intravenously once daily
None Documented
None Documented
Clinical Note
moderateSertraline + Desmopressin
"The risk or severity of adverse effects can be increased when Sertraline is combined with Desmopressin."
Clinical Note
moderateSertraline + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Sertraline."
Clinical Note
moderateSertraline + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Sertraline."
Clinical Note
moderateSertraline + Cyclosporine
Terminal elimination half-life: 4.1 hours (range 3.3–4.7 h) after single oral dose; steady state: 4.4 h. No clinically relevant accumulation.
Terminal elimination half-life is 12–18 hours in patients with normal renal function (CrCl >90 mL/min). In moderate renal impairment (CrCl 30–59 mL/min), half-life extends to 24–36 hours. Clinical context: Dosing interval adjustment required for CrCl <60 mL/min.
Renal: 99% (tapentadol and glucuronide conjugates); Fecal: <1%; unchanged tapentadol: <5%.
Approximately 70% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion; 30% is eliminated in feces via biliary secretion. Total renal clearance accounts for 85% of systemic clearance.
Category C
Category C
Opioid Analgesic
Opioid Analgesic
"The metabolism of Cyclosporine can be decreased when combined with Sertraline."